Deletion of a pseudogene within a fragile site triggers the oncogenic expression of the mitotic CCSER1 gene.
Journal
Life science alliance
ISSN: 2575-1077
Titre abrégé: Life Sci Alliance
Pays: United States
ID NLM: 101728869
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
13
01
2021
revised:
12
06
2021
accepted:
14
06
2021
entrez:
30
6
2021
pubmed:
1
7
2021
medline:
15
12
2021
Statut:
epublish
Résumé
The oncogenic role of common fragile sites (CFS), focal and pervasive gaps in the cancer genome arising from replicative stress, remains controversial. Exploiting the TCGA dataset, we found that in most CFS the genes residing within the associated focal deletions are down-regulated, including proteins involved in tumour immune recognition. In a subset of CFS, however, the residing genes are surprisingly overexpressed. Within the most frequent CFS in this group, FRA4F, which is deleted in up to 18% of cancer cases and harbours the CCSER1 gene, we identified a region which includes an intronic, antisense pseudogene, TMSB4XP8. TMSB4XP8 focal ablation or transcriptional silencing elicits the overexpression of
Identifiants
pubmed: 34187875
pii: 4/8/e202101019
doi: 10.26508/lsa.202101019
pmc: PMC8321653
pii:
doi:
Substances chimiques
CCSER1 protein, human
0
Cell Cycle Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA010815
Pays : United States
Informations de copyright
© 2021 Santoliquido et al.
Références
Am J Pathol. 2013 Jul;183(1):296-303
pubmed: 23665203
Nat Commun. 2016 Oct 07;7:13031
pubmed: 27713408
Nat Med. 2019 Apr;25(4):603-611
pubmed: 30911134
Nat Commun. 2015 Dec 04;6:8971
pubmed: 26634437
Elife. 2019 Apr 26;8:
pubmed: 31025937
Nature. 2010 May 13;465(7295):182-7
pubmed: 20393465
FASEB J. 2019 Mar;33(3):3481-3495
pubmed: 30452881
Cell. 2016 Sep 22;167(1):219-232.e14
pubmed: 27662090
Genes Genomics. 2019 Feb;41(2):193-199
pubmed: 30298359
Nat Commun. 2016 Nov 28;7:13610
pubmed: 27892455
FEBS J. 2012 Oct;279(19):3549-3558
pubmed: 22846345
PLoS One. 2013 Jun 21;8(6):e66264
pubmed: 23805207
Front Med (Lausanne). 2015 Sep 25;2:68
pubmed: 26442270
Nat Commun. 2014 Apr 09;5:3644
pubmed: 24714652
PLoS Genet. 2016 Dec 15;12(12):e1006436
pubmed: 27977694
Nat Rev Cancer. 2017 Jul 25;17(8):489-501
pubmed: 28740117
Nature. 2010 Feb 18;463(7283):899-905
pubmed: 20164920
Cancer Cell. 2014 Aug 11;26(2):160-1
pubmed: 25117708
Nature. 2010 Feb 18;463(7283):893-8
pubmed: 20164919
Int J Cancer. 2007 Jun 1;120(11):2359-67
pubmed: 17290399
Oncotarget. 2011 Jan-Feb;2(1-2):69-75
pubmed: 21378412
Mol Ther. 2013 May;21(5):934-46
pubmed: 23439497
Cell. 2011 Aug 5;146(3):353-8
pubmed: 21802130
Nat Rev Genet. 2013 Dec;14(12):880-93
pubmed: 24217315
Nat Genet. 2013 Oct;45(10):1134-40
pubmed: 24071852
Nat Genet. 2006 Sep;38(9):1043-8
pubmed: 16921376
Curr Protoc Bioinformatics. 2014 Sep 08;47:11.12.1-34
pubmed: 25199790
Am J Hum Genet. 2019 Sep 5;105(3):573-587
pubmed: 31447096
PLoS Genet. 2010 Mar 05;6(3):e1000869
pubmed: 20221260
Cancer Res. 2008 Jun 1;68(11):4163-72
pubmed: 18519675